Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods

International Journal of Pharmaceutics

Volumn 242, Issue 1-2, 2002, Pages 197-201

  Gibaud, Stéphane ^a   Bonneville, Aurélie ^a   Astier, Alain ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

3,4 Diaminopyridine; Microparticles; Poly( caprolactone); Polymer; Sustained release

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETONE; EUDRAGIT RS; MICROSPHERE; MINERAL OIL; PHOSPHATE; SOLVENT;

ARTICLE; CRYSTAL; DISPERSION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EVAPORATION; PARTICLE SIZE; PH; POWDER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

4-AMINOPYRIDINE; ACRYLIC RESINS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; EXCIPIENTS; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; POLYESTERS; SOLVENTS;

EID: 0037151423     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00157-6     Document Type: Article

References (14)

1. A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit
2. 3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis
3. The current status of studies of aminopyridines in patients with multiple sclerosis
4. Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial
5. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis
6. Microencapsulation of antimicrobial ceftiofur drugs
7. Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. I. Methods and morphology
8. The effects of 3,4-diaminopyridine on acetylcholine release at the frog neuromuscular junction
9. Analysis of 3,4-diaminopyridine in human serum by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection
10. 4-aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis
11. 3,4-diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)
12. An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis
13. Commentary: Aminopyridines, and synaptic transmission
14. Preparation and characterization of ethylcellulose microspheres containing 5-fluorouracil